PANTHERx® Rare Pharmacy Selected by Rhythm Pharmaceuticals to Distribute IMCIVREE™ (setmelanotide) for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announced today that it was selected by Rhythm Pharmaceuticals...
Read More
Centene Signs Definitive Agreement to Acquire PANTHERx Rare Pharmacy (PANTHERx)
Today is a transformative day and the culmination of a great deal of effort and diligence to support the future of PANTHERx....
Read More
Dr. Gordon J. Vanscoy, Chairman & CEO of PANTHERx Rare & RareMed Solutions, Named an EY Entrepreneur Of The Year® 2020 National Award Winner
Read the Official PANTHERx Press Release. Ernst & Young LLP (EY US) yesterday announced that Dr. Gordon J. Vanscoy, Chairman...
Read More
PANTHERx® Rare Pharmacy Selected by Blueprint Medicines to Distribute GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Blueprint Medicines...
Read More
PANTHERx® Rare Pharmacy Selected by Ultragenyx Pharmaceutical to Distribute DOJOLVI™ (triheptanoin), for Patients with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Ultragenyx Pharmaceutical...
Read More
PANTHERx® Chosen as Exclusive Rare Pharmacy Partner by Viela Bio, Inc. for Uplizna™ (inebilizumab-cdon) for Adult Patients with AQP4+ Neuromyelitis Optica Spectrum Disorder (NMOSD)
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Viela Bio, Inc....
Read More
